“…To address such issues, comprehensive screening of cancer drug candidates was introduced, aiming to find suitable candidates with effective dose to treat cancer but with less side effects 4 . However, in the in-vivo context, preclinical mammalian models are difficult to be used as a high-throughput screening platform due to economical and ethical issues 5 . To increase the chance to obtain prospective anticancer drug candidates with desired properties, the use of fruit fly Drosophila melanogaster as an in-vivo preclinical model has been introduced.…”